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Abstract
Purpose: In recent studies, we showed that TP53 gene
mutation or high levels of cytosolic vascular endothelial
growth factor (VEGF) in estrogen receptor (ER)--positive
primary breast tumors predict a poor disease outcome for
patients treated with first-line tamoxifen for advanced dis-
ease. Mutant TP53 may up-regulate VEGF, whereas, on
the other hand, wild-type TP53 may decrease VEGF pro-
duction.
Experimental Design: In the present study, we aimed to
assess the combined predictive value of TP53 gene mutation
and VEGF status of 160 advanced breast cancer patients
with ER-positive tumors who were treated with tamoxifen
(median follow-up from start of tamoxifen treatment, 64
months). To assess TP53 gene mutation status, the entire
open reading frame was sequenced; for VEGF status, an
ELISA was used.
Results: In univariate analysis, both TP53 gene muta-
tion (28% of the tumors) and a VEGF level above the
median value were significantly associated with a short
progression-free survival, post-relapse overall survival, and
a poor rate of response to tamoxifen. In Cox multivariate
regression analysis including the traditional predictive fac-
tors, the addition of TP53 gene mutation and VEGF status,
alone or in combination, significantly predicted a poor effi-
cacy of tamoxifen treatment. When the two factors were
combined, a significantly decreased odds ratio was seen for
the rate of response (odds ratio, 0.27). Similarly, an in-
creased hazard ratio (HR) was seen for progression-free
survival (HR, 2.32) and post-relapse overall survival (HR,
1.68) in the group with mutant TP53 and high VEGF com-
pared with the group with both risk factors absent.
Conclusions: Combined TP53 gene mutation status and
high VEGF levels of ER-positive primary breast tumors
independently predict a poor course of the disease of pa-
tients with advanced breast cancer treated with tamoxifen.
These patients, having unfavorable tumor characteristics,
might benefit more from other types of (individualized)
treatment protocols.
Introduction
Although tamoxifen is the endocrine treatment of choice
for all stages of breast cancer (1), approximately one-half of the
patients with ER3--positive breast tumors either do not respond
or rapidly develop resistance to tamoxifen treatment. Because
response rates in patients with ER--negative primary tumors
are low, resistance to this nonsteroidal antiestrogen is a major
clinical problem. A large number of cell biological factors, other
than ER, were shown to be related with a favorable or poor type
of response to endocrine treatment (for review, see Ref. 2). The
estrogen-regulated PgR or pS2 gene expression has, for exam-
ple, been associated with a favorable response. Conversely,
other tumor cell biological factors, tyrosine kinases such as
epidermal growth factor receptor (3) or its family member
HER2 (4), the tumor suppressor gene TP53 (5), urokinase-type
plasminogen activator (6), human kallikrein 10 (7), and VEGF
(vascular permeability factor; Ref. 8), were associated with a
poor response of metastatic breast cancer to tamoxifen.
VEGF is a potent angiogenic factor, and the common
oncogenes and tumor suppressor genes associated with neoplas-
tic cell transformation also play an integral part in activating the
angiogenic switch. Alterations in these genes, including RAS,
SRC, HER2, and TP53, have been characterized as inducers of
VEGF expression (9). Mutant TP53 is reported to up-regulate
VEGF, whereas wild-type TP53 may decrease VEGF produc-
tion and increase levels of the angiogenesis inhibitors (10).Received 9/16/03; revised 12/4/03; accepted 12/16/03.
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Interestingly, Pal et al. (11) recently showed a direct effect of
TP53 on VEGF, in that TP53 makes a complex with Sp1 and
thereby inhibits Sp1-mediated VEGF transcriptional activation
in breast cancer cell lines.
In view of the facts that (a) TP53 regulates VEGF produc-
tion, (b) TP53 and VEGF each predict a poor efficacy of
tamoxifen treatment in ER-positive primary breast cancer (5, 8),
and (c) the combined VEGF with TP53 status resulted in better
survival prediction in primary breast cancer (12), we hypothe-
sized that combining these biological factors may give addi-
tional information on tamoxifen response in patients with ad-
vanced breast cancer.
In the present study, we aimed to assess whether the
combined VEGF and TP53 status may be predictive for the type
of response to tamoxifen therapy, PFS, and PR-OS in a series of
ER-positive patients with advanced breast cancer.
Materials and Methods
Patients and Treatment. Our study design was ap-
proved by the medical ethical committee of the Erasmus MC
(Rotterdam, the Netherlands). To evaluate the predictive value
of combined TP53 gene mutation and cytosolic VEGF status in
relation to tamoxifen treatment in patients with advanced breast
cancer, the 160 ER-positive tumors (10 fmol/mg protein)
overlapping from earlier studies on the predictive value of TP53
gene mutation (5) and VEGF protein levels (8) were used. The
HER2 status is not known. All of the patients received tamox-
ifen (40 mg daily) as first-line treatment after diagnosis of
advanced disease (median age, 61 years; range, 33–82 years).
At the start of tamoxifen treatment, 125 (78%) patients were
postmenopausal, and 35 (22%) were premenopausal. None of
the patients had received neoadjuvant therapy or were exposed
to hormonal treatment at an earlier stage. Eleven patients (7%)
were diagnosed with metastatic disease (M1) at time of primary
surgery (breast-conserving lumpectomy, 51 patients; modified
mastectomy, 109 patients). Twenty-one patients (13%) received
systemic adjuvant chemotherapy [cyclophosphamide, metho-
trexate, and 5-fluorouracil (CMF), 14 patients; cyclophospha-
mide, Adriamycin, and 5-fluorouracil (CAF), 7 patients]. The
median follow-up of patients alive is 108 months (range, 66–
167 months) from primary surgery, and 64 months (range,
21–100 months) from the onset of tamoxifen treatment. During
follow-up, 140 patients (88%) have died with a median survival
time of 24 months. Tumor progression occurred in 157 (98%) of
the patients. After tumor progression on first-line tamoxifen
treatment, 118 patients were treated with one or more additional
endocrine agents (mainly high-dose progestins), whereas, thus
far, 100 patients were subsequently treated with one or more
regimens of chemotherapy (mainly CMF or CAF) after the
occurrence of hormonal resistance. Criteria for PFS, PR-OS, and
type of response were described previously (8). As explained,
CR and PR (CR, 13 patients; PR, 18 patients) and SDis for more
than 6 months (SDis, 64 patients) were combined for overall
response (8).
Assays of TP53 Gene Mutation and VEGF. Results
from the cDNA-based sequencing of the entire open reading
frame (exons 2 through 11) of the TP53 gene were taken from
Berns et al. (5). The results of the measurements of the cytosolic
levels of VEGF isoforms 121 and 165, ER, and PgR were taken
from Foekens et al. (8).
Statistics. The strength of the associations of VEGF with
ER and PgR were tested with Spearman rank correlation (rs).
The associations of VEGF (used as a continuous variable) with
other variables (used as grouping variables) were tested with the
nonparametric Wilcoxon rank-sum test or the Kruskal-Wallis
test. The associations of TP53 gene mutation with other vari-
ables were tested with the Pearson’s 2 test, whereas the Wil-
coxon rank-sum test was used to test the association between
PgR and gene mutation. In uni- and multivariate analysis, the
relation with response to therapy was examined with logistic
regression analysis, and the ORs were calculated. Cox univari-
ate and multivariate regression analysis was used in the analysis
of PFS and PR-OS, and HRs were calculated. The associated
likelihood ratio test was used to test for differences between
multivariate models with variables included and excluded. ORs
and HRs are presented with their 95% CIs. Survival curves were
generated using the method of Kaplan and Meier, and the
log-rank test for trend was used to examine survival data. For all
tests, all available data during the follow-up period were in-
cluded. All computations were performed with the STATA
statistical package, release 7.0 (STATA Corp., College Station,
TX). All Ps are two-sided.
Results
VEGF Levels, TP53 Gene Status, and Associations.
The entire open reading frame of the TP53 gene of 160 female
breast tumors was sequenced. Mutations were detected in 44
(28%) of the tumors, of which 33 were missense mutations. The
remaining 11 mutations (referred to as nonmissense mutations)
included 3 in-frame deletions/insertions and 8 nonsense or
frameshift mutations, both leading to a premature stop codon.
Therefore, one-fourth of the mutations would be false negatives
when immunohistochemical analyses were used to assess the
TP53 status.
The relationships of TP53 gene mutation and the level of
VEGF with patient and tumor characteristics and with each
other are listed in Table 1. The median level of VEGF deter-
mined in all 160 cytosols was 0.22 ng/mg protein (range, 0–27
ng/mg protein). Consistent with the reported up-regulation of
VEGF by mutant TP53 and down-regulation by wild-type TP53,
in cytosols prepared from 44 tumors with a TP53 gene mutation,
the median VEGF level (0.39 ng/mg protein) was twice as high
(P  0.04) compared with the 116 cytosols prepared from
tumors without a TP53 gene mutation (0.19 ng/mg protein). Of
the 44 tumors with a TP53 gene mutation, higher cytosolic
levels of VEGF were found in the 11 tumors with a nonmissense
mutation (median, 0.43 ng/mg protein) compared with the 33
tumors with a missense mutation (0.30 ng/mg protein). This
difference was not statistically significant (P  0.21). In the
present series of 160 tumors, the prevalence of TP53 gene
mutation and the levels of VEGF, in accordance with their
reported association with a poor prognosis in primary breast
cancer, are highest in tumors of patients with a short DFI (Table
1). There were no significant relationships between the preva-
lence of TP53 gene mutation or the level of VEGF and the levels
of ER (data not shown) or PgR within these ER-positive tumors
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(Table 1). In an exploratory analysis, the factors were combined
and related to the dominant site of relapse. Those tumors with no
mutation and low (n  63) or high (n  53) levels of VEGF,
respectively, revealed bone (51% or 60%, respectively) and
viscera (38% or 32%, respectively) as dominant sites of relapse.
In tumors with a TP53 gene mutation but with low levels of
VEGF (n  17), bone was the dominant site of relapse (47%),
followed by soft tissue (29%) and viscera (24%). In contrast, for
those tumors with high levels of VEGF and with a TP53
mutation (n  27), viscera (52%) was the main site of relapse,
followed by bone (33%) and soft tissue (15%).
Univariate and Multivariate Analysis for PFS and PR-
OS. In Cox univariate regression analysis, TP53 gene muta-
tion status was associated with a poor PFS (HR, 1.53; 95% CI,
1.08–2.19; P  0.02) and PR-OS (HR, 1.56; 95% CI, 1.08–
2.26; P  0.02). Similarly, a high level of VEGF (equal to or
above the median value of 0.22 ng/mg protein) was associated
with a short PFS (HR, 1.55; 95% CI, 1.12–2.13; P 0.007) and
PR-OS (HR, 1.63; 95% CI, 1.16–2.29; P  0.005). To assess
whether there was an independent relationship of these factors
with PFS or PR-OS, Cox multivariate regression analysis was
performed. After inclusion of the traditional predictive factors
age and menopausal status, dominant site of relapse (bone
versus soft tissue, viscera versus soft tissue, DFI of 1 year
versus 1 year), ER and PgR (both as a continuous variable),
and stepwise elimination of the nonsignificant variables, a base
model containing dominant site of relapse and DFI was defined
(Table 2). The other factors, as well as adjuvant chemotherapy
(which was added as an indicator variable), did not significantly
add to the multivariate models for PFS and PR-OS in these
ER-positive tumors. When added separately or together to the
base model for PFS, TP53 gene mutation and a high VEGF level
both independently predicted a poor PFS. The increase in 2
(2) by the addition of TP53 gene mutation and VEGF sta-
tus as a combined variable to the base model of PFS was 11.0
(d.f.  2; P  0.004). Similarly, in analysis for PR-OS, the
addition of the combined variable showed a 2 of 8.0 (d.f. 
2; P  0.02).
In Kaplan-Meier analysis as a function of combined TP53
gene mutation and VEGF status, patients with a nonmutated
TP53 gene and a low VEGF level in their primary tumor showed
the longest PFS (Fig. 1A) and PR-OS (Fig. 1B), with a median
time to progression and death of 10 and 35 months, respectively.
Patients with tumors containing one of two of the unfavorable
factors showed an intermediate PFS (median, 8 months; HR,
1.46; 95% CI, 1.03–2.08; P  0.03) and PR-OS (median, 23
months; HR, 1.69; 95%, 1.16–2.45; P  0.006), and those with
both a TP53 gene mutation and a high VEGF level showed the
shortest PFS (median, 5 months; HR, 2.17; 95% CI, 1.37–3.44;
P  0.001) and PR-OS (median, 19 months; HR, 2.13; 95% CI,
1.31–3.46; P  0.002).
Response to Tamoxifen Treatment. Of the 160 pa-
tients, 95 (59%) responded (13 CR, 18 PR, and 64 SDis) with a
median duration of response of 14 months (range, 3–71
months). In tumors with a TP53 gene mutation or a high level of
VEGF, the overall response rates were 45% (OR, 0.46; 95% CI,
0.23–0.92; P  0.03) for tumors with a mutated TP53 gene and
51% (OR, 0.51; 95% CI, 0.27–0.96; P  0.04) for those with
high levels of VEGF. Consistent with the results observed in the
analyses of PFS and PR-OS, in multivariate logistic regression
analysis for response, the combined variable of TP53 gene
mutation and VEGF status independently (2  6.3; d.f.  2;
Table 1 Relationships of TP53 gene status and VEGF with patient and tumor characteristics
Characteristic Frequency
Mutated TP53 gene VEGF
No. (%) P Median value (quartiles)a P
All patients 160 44 (28) 0.22 (0, 0.75)
Menopausal statusb
Premenopausal 55 12 (22) 0.18 (0, 0.43)
Postmenopausal 105 32 (30) 0.24c 0.23 (0.02, 0.79) 0.15d
Dominant site of relapsee
Soft tissue 20 9 (45) 0.12 (0, 0.52)
Bone 81 17 (21) 0.22 (0.02, 0.56)
Viscera 59 18 (31) 0.08c 0.28 (0, 0.81) 0.54f
DFI
1 yr 45 18 (40) 0.48 (0.18, 2.34)
1 yr 115 26 (23) 0.03c 0.17 (0, 0.45) 0.0001d
PgR statusg
Negative 24 8 (33) 0.34 (0.10, 0.48)
Positive 135 36 (27) 0.13d 0.20 (0, 0.78) 0.48h
TP53 gene mutation
No 116 0.19 (0, 0.54)
Yes 44 0.39 (0.10, 1.45) 0.04d
a All of the values are in ng/mg protein (25th and 75th percentiles).
b At time of primary surgery.
c P for Pearson’s 2 test.
d P for Wilcoxon’s rank-sum test.
e In case of multiple sites, the site with the worst prognosis was considered dominant.
f P for Kruskal-Wallis test.
g Cutoff point used: 10 fmol/mg protein. PgR value is missing for one patient.
h P for Spearman rank correlation.
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P  0.04) added to the model containing dominant site of
relapse and DFI. Compared with tumors with both a wild-type
TP53 gene and a low level of VEGF (response rate, 71%; OR,
1), those without a TP53 gene mutation and a high level of
VEGF (response rate, 57%; OR, 0.64; 95% CI, 0.28–1.46; P 
0.29) or with a TP53 gene mutation and a low level of VEGF
(response rate, 53%; OR, 0.29; 95% CI, 0.08–1.03; P  0.06)
showed an intermediate response. However, when both factors
are unfavorable (response rate, 41%; OR, 0.27; 95% CI, 0.09–
0.79; P  0.02) patients showed the poorest rate of responses.
Discussion
Breast cancer is a multifactorial disease, and genetic alter-
ations lead to transformation of normal cells into cancer cells.
Human breast cancer is an angiogenesis-dependent tumor that
initially depends on estrogens for development and progression.
The ER-, which is expressed in about 75% of breast tumors, is
the target for estrogen antagonists, such as tamoxifen. In the
present study, we evaluated the predictive value of combined
TP53 genotype and VEGF expression status in a series of 160
ER--positive breast cancer patients who were treated with
tamoxifen for advanced disease.
Our study demonstrates a statistically significant associa-
tion between TP53 mutations and higher VEGF expression
levels in human breast tumor samples. Moreover, tumors with
nonmissense mutations, which are not likely to be detected by
protein-based methods, were found to have the highest VEGF
expression levels. These correlations had been reported earlier
in breast tumors by Linderholm et al. (12) and are consistent
with the reported up-regulation of VEGF by mutant TP53 (11).
The association between loss of wild-type TP53 and increased
VEGF levels indicates that angiogenic activity may, at least in
part, depend on altered TP53 function in breast tumors. In the
present study, the median level was chosen as a cutoff for VEGF
because otherwise subsets, particularly the combined TP53/
VEGF subset, would have been too small for meaningful sta-
tistical analyses.
With respect to the predictive value, we and others have
shown that only TP53 genotype, and not immunohistochemical
results, is predictive for the type of response to (adjuvant)
tamoxifen treatment in breast cancer patients [as shown in seven
studies with a total of approximately 1500 patients (reviewed in
Ref. 5; see Ref. 12)]. Few studies have shown that VEGF status
is a significant predictor of poor outcome in patients receiving
(adjuvant) endocrine therapy with tamoxifen (8, 12, 13). These
effects were stronger in the ER--positive subset. Our present
study shows for the first time that in patients with advanced
breast cancer, the combined TP53 gene and VEGF status gives
additional predictive information for disease outcome in the
ER--positive subset. In multivariate analysis for response, the
relationship between combined factors and response to tamox-
ifen in the ER--positive tumors remained significant, even
after correction for the traditional predictive factors. Thus, by
using the TP53-VEGF status, one can basically predict that 70%
of the ER--positive patients with wild-type TP53 and low
VEGF levels will respond to tamoxifen treatment. Similarly, the
longest PFS and PR-OS were observed for patients with wild-
type TP53 and low VEGF levels, and the shortest PFS and
PR-OS were observed for those with mutant TP53 and high
VEGF levels, both in univariate and multivariate analysis. No
other investigations have yet evaluated the type of response to
tamoxifen as a function of VEGF levels and the complete TP53
gene status.
At present, there is no clear mechanism that explains the
association between VEGF, TP53, and poor outcome of tamox-
ifen in ER--positive breast tumors. However, several preclin-
ical and clinical studies may provide a basis. There is evidence
that VEGF production is regulated by estrogens in vitro and in
vivo, although data are conflicting. Whereas Hyder et al. (14)
showed the presence of estrogen response elements in the VEGF
gene, they have not been able to show estrogen response in
various breast cancer cell types (15). Others have reported
estrogen induction of VEGF (16). The estrogen induction of
VEGF in DMBA tumors was shown by Nakamura et al. (17).
Table 2 Multivariate analysis for PFS and PR-OS after start of first-line tamoxifen treatment in patients with advanced breast cancera
PFS PR-OS
P HR (95% CI) P HR (95% CI)
Base model
Dominant site of relapseb
Bone vs. soft tissue 0.07 1.61 (0.96–2.69) 0.57 1.18 (0.67–2.07)
Viscera vs. soft tissue 0.03 1.81 (1.06–3.08) 0.03 1.90 (1.07–3.37)
DFI
1 yr vs. 1 yr 0.001 0.55 (0.39–0.79) 0.001 0.43 (0.29–0.62)
Additions to base model
TP53 gene mutation (yes vs. no)c 0.01 1.65 (1.14–2.38) 0.09 1.42 (0.96–2.10)
VEGF status (high vs. low)c,d 0.02 1.48 (1.06–2.05) 0.04 1.45 (1.02–2.04)
TP53 gene mutation/VEGF statusd,e
No TP53 mutation  VEGF-low 1 1
TP53 mutation or VEGF-high 0.04 1.45 (1.02–2.07) 0.01 1.66 (1.14–2.42)
TP53 mutation  VEGF-high 0.01 2.32 (1.40–3.83) 0.05 1.68 (1.00–2.82)
a All multivariate models included 160 patients.
b In case of multiple sites, the site with the worst prognosis was considered dominant.
c Added separately to the base model.
d Low, below the median value of 0.22 ng/mg protein; high, 0.22 ng/mg protein.
e Added as a combined variable to the base model.
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This supports the hypothesis that estrogens regulate VEGF
expression, at least in part, via transcriptional effects of ER. In
contrast to the previous study, Schafer et al. (18) reported that
VEGF expression was not increased in MCF-7 tumors after
estradiol stimulation but was increased only after tamoxifen
treatment. However, this tamoxifen-induced expression of
VEGF in MCF-7 cells was reported not to be mediated by ER
(16). Furthermore, Adams et al. (19) showed that tamoxifen
treatment of breast cancer patients resulted in higher circulating
and platelet-derived VEGF levels in those patients with ER-
positive breast cancer in remission. Thus, a stimulating effect of
estrogens or tamoxifen on VEGF production is possible, but
additional studies are needed to elucidate the mechanism(s).
In summary, the present study shows that knowledge of the
geno- and phenotype of breast tumors is important for finding
targets for treatment. Treatments aimed at combining (pure)
antiestrogens with inhibitors of angiogenesis (e.g., drugs block-
ing VEGF or its receptor) could be beneficial for those patients
with wild-type TP53, ER--positive, and VEGF-positive tu-
mors. However, based on the findings of Yu et al. (20), those
breast tumors that have mutant TP53 instead might be better
treated with angiogenesis inhibitors and drugs that specifically
target hypoxic cells. Nonetheless, only if validated in homoge-
neous, multicenter, prospective studies, the clinical relevance of
the combined ER-, TP53, and VEGF status can be assessed for
novel therapeutic strategies.
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